International myeloma grand round

Lancet Oncology

Volumn 2, Issue 9, 2001, Pages 571-579

  Sirohi, Bhawna ^a   Powles, Ray ^a   Harousseau, Jean Luc ^a,b,c,d  

^a Serv d'Hématologie Clinique   (France)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Department of Hematology Oncology Cedars Sinai Comprehensive Cancer Center   (United States)

^d Royal Marsden Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; HUMAN; MALE; MULTIPLE MYELOMA;

ADULT; HUMANS; MALE; MULTIPLE MYELOMA;

EID: 0035469641     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00491-0     Document Type: Review

References (27)

1. Durie B.G.M., Salmon S.E. A clinical staging system for multiple myeloma. Cancer. 36:1975;842-854.
2. Raje N., Powles R.L., Kulkarni S., et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophophamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol. 97:1997;153-160.
3. Cunningham D., Powles R., Malpas J., et al. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results. Br J Haematol. 102:1998;495-502.
4. Cunningham D., Paz-Ares L., Milan S., et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 2:1994;759-763.
5. Barlogie B., Jagannath S., Vesole D.H., et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 89:1997;789-793.
6. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 335:1996;91-97.
7. Attal M., Harousseau J.L. Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Prac Res Clin Haematol. 12:1999;171-191.
8. Barlogie B., Jagannath S., Desikan K.R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 93:1999;55-65.
9. Facon T., Avet-Loiseau H., Guillerm G., et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 97:2001;1566-1571.
10. Moreau P., Harousseau J.L., Wijdenes J., et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response ratesin advanced multiple myeloma. Br J Haematol. 109:2000;661-664.
11. Mundy G.R. Myeloma bone disease. Br J Cancer. 34:1998;246-251.
12. Mundy G.R. Mechanisms of osteolytic bone destruction. Bone. 12:(Suppl. 1):1991;S1-6.
13. Oyajobi B.O., Anderson D.M., Traianedes K., et al. Therapeutic efficacy of a soluble receptor of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61:2001;2572-2578.
14. 1-integrin enhances production of osteoclast-stimulating activity. Blood. 96:2000;1953-1960.
15. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 334:1996;488-493.
16. Tricot G., Barlogie B., Jagannath S., et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 86:1995;4250-4256.
17. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 98:2001;210-216.
18. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptoses, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61:2001;3071-3076.
19. Mendel D.B., Laird A.D., Smolich B.D., et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15:2000;29-41.
20. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 98:2001;492-494.
21. Durie BGM, Stepan DE. Low dose thalidomide: alone and in combination. Proc VIIIth International Myeloma Workshop, Banff, Canada, 2001; S67: 111 (abstr).
22. Rajkumar SV. Angiogenesis and Anti-angiogenic therapy with Thalidomide for myeloma. Proc VIIIth International Myeloma Workshop, Banff, Canada 2001; S68: 112 [abstract].
23. Powles R.L., Raje N., Milan S., et al. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant. 20:1997;435-443.
24. Kulkarni S., Powles R.L., Treleaven J., et al. Impact of previous high dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant. 23:1999;675-680.
25. McElwain T.J., Powles R.L. High dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet. 2:1983;822-824.
26. Selby P.J., McElwain T.J., Nandi A., et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 66:1987;55-62.
27. Sirohi B., Powles R., Sumpter K., et al. A comparison of kinetics of paraprotein clearance: rapid decline of paraprotein after high dose melphalan (HDM) versus infusional chemotherapy (IC) in previously untreated patients with IgG multiple myeloma (abstr). Bone Marrow Transplant. 25:2000;917.